title: [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
abstract: Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer. The protocol of this therapy was as follows: On day 1, 500 mg/body cyclophosphamide (CPM) was administered by drip infusion, and on day 2, 200 mg/m2 methotrexate (MTX) was infused intravenously for 30 min; immediately after, 500 mg/body 5-fluorouracil (5-FU) was injected by bolus infusion for 5-10 min. On day 3, 24 hours after MTX administration, leucovorin rescue was added. This combination chemotherapy was repeated every two weeks. As a result, 35 of 52 patients were evaluable and the response rate (CR + PR) was investigated; 2/21 (9.5%) for gastric, 2/7 (28.6%) for breast, and 0% for miscellaneous. As complications for side effect, general fatigue, anorexia, nausea, vomiting and stomatitis were observed symptomatically, and leukopenia and thrombocytopenia were recognized in laboratory data as dose limiting factors.
authors.affiliation: Dept. of Surgery, Medicine and Biology, Hiroshima University.
authors.forename: T
authors.initials: T
authors.lastname: Saeki
authors.forename: K
authors.initials: K
authors.lastname: Jinushi
authors.forename: R
authors.initials: R
authors.lastname: Kim
authors.forename: M
authors.initials: M
authors.lastname: Toi
authors.forename: K
authors.initials: K
authors.lastname: Saeki
authors.forename: K
authors.initials: K
authors.lastname: Yoshinaka
authors.forename: E
authors.initials: E
authors.lastname: Yanagawa
authors.forename: M
authors.initials: M
authors.lastname: Niimoto
authors.forename: T
authors.initials: T
authors.lastname: Hattori
mesh_terms: D000855:Anorexia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005221:Fatigue / Q000139:chemically induced; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate